keyword
MENU ▼
Read by QxMD icon Read
search

hematologica

keyword
https://www.readbyqxmd.com/read/27759829/analysis-of-cytokine-profile-and-growth-factors-in-platelet-rich-plasma-obtained-by-open-systems-and-commercial-columns
#1
Alberto de Castro Pochini, Eliane Antonioli, Daniella Zanetti Bucci, Luiz Roberto Sardinha, Carlos Vicente Andreoli, Mario Ferretti, Benno Ejnisman, Anna Carla Goldberg, Moisés Cohen
Objective: To evaluate growth factors and cytokines in samples of platelet-rich plasma obtained by three different centrifugation methods. Methods: Peripheral blood of six individuals with no hematological diseases, aged 18 to 68 years, was drawn to obtain platelet-rich plasma, using the open method and commercial columns by Medtronic and Biomet. The products obtained with the different types of centrifugation were submitted to laboratory analysis, including pro-inflammatory cytokines and chemokines by flow cytometry assays, the concentration of fibroblast growth factors-2 (FGF-2) and transforming growth factor-beta1 (TGF-β1)...
July 2016: Einstein
https://www.readbyqxmd.com/read/27759828/implementing-a-clinical-pharmacy-service-in-hematology
#2
Tatiane Fernandes Farias, Karina da Silva Aguiar, Inajara Rotta, Klezia Morais da Silva Belletti, Juliane Carlotto
Objective: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. Methods: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters)...
July 2016: Einstein
https://www.readbyqxmd.com/read/27269220/-not-available
#3
María Ballesteros-Pomar, Rocío Villar-Taibo, Alicia Calleja-Fernández, Begoña Pintor-de-la-Maza, Cecilia Álvarez-Del-Campo, Alfonso Vidal-Casariego, Isidoro Cano-Rodríguez
Los datos del estudio PREDYCES® nos revelaron que en España la desnutrición relacionada con la enfermedad (DRE) afecta a uno de cada cuatro pacientes hospitalizados. Esta cifra aumenta hasta el 36,8% en los pacientes hematológicos. Se calcula que un 20% de los pacientes oncológicos muere por complicaciones relacionadas con la DRE. Nuestro grupo se planteó en 2011 comenzar la implantación de un cribado nutricional en los servicios con mayor riesgo de DRE. La presente revisión trata de describir todo el proceso que hemos seguido para mejorar la situación nutricional en los pacientes ingresados en el Servicio de Hematología del Complejo Asistencial Universitario de León (CAULE), mayoritariamente con diagnóstico de neoplasias hematológicas...
2016: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
https://www.readbyqxmd.com/read/26630574/a-low-frequency-of-losses-in-11q-chromosome-is-associated-with-better-outcome-and-lower-rate-of-genomic-mutations-in-patients-with-chronic-lymphocytic-leukemia
#4
José Ángel Hernández, María Hernández-Sánchez, Ana Eugenia Rodríguez-Vicente, Vera Grossmann, Rosa Collado, Cecilia Heras, Anna Puiggros, Ana África Martín, Noemí Puig, Rocío Benito, Cristina Robledo, Julio Delgado, Teresa González, José Antonio Queizán, Josefina Galende, Ignacio de la Fuente, Guillermo Martín-Núñez, José María Alonso, Pau Abrisqueta, Elisa Luño, Isabel Marugán, Isabel González-Gascón, Francesc Bosch, Alexander Kohlmann, Marcos González, Blanca Espinet, Jesús María Hernández-Rivas
To analyze the impact of the 11q deleted (11q-) cells in CLL patients on the time to first therapy (TFT) and overall survival (OS), 2,493 patients with CLL were studied. 242 patients (9.7%) had 11q-. Fluorescence in situ hybridization (FISH) studies showed a threshold of 40% of deleted cells to be optimal for showing that clinical differences in terms of TFT and OS within 11q- CLLs. In patients with ≥40% of losses in 11q (11q-H) (74%), the median TFT was 19 months compared with 44 months in CLL patients with <40% del(11q) (11q-L) (P<0...
2015: PloS One
https://www.readbyqxmd.com/read/26089271/-hematologic-response-predictor-factors-in-adults-with-myelodysplastic-syndromes-smd-treated-with-cyclosporin-a-csa
#5
Elia Zamora-Pérez, Xavier López-Karpovitch
BACKGROUND: Myelodysplastic syndromes (MDS) are clonal diseases of hematopoietic cells. The International Prognostic Scoring System (IPSS) is the risk scale most employed in MDS. Cyclosporin A (CsA) has been used in the treatment of cytopenias in MDS. OBJECTIVE: To evaluate hematologic response and identify response predictive factors in adults with MDS treated with CsA. MATERIAL AND METHODS: Patients with MDS diagnosed according World Health Organization (WHO) classification were recruited from January 1997 to June 2012...
May 2015: Gaceta Médica de México
https://www.readbyqxmd.com/read/25689772/a-high-proportion-of-cells-carrying-trisomy-12-is-associated-with-a-worse-outcome-in-patients-with-chronic-lymphocytic-leukemia
#6
Isabel González-Gascón Y Marín, María Hernández-Sánchez, Ana-Eugenia Rodríguez-Vicente, Carmen Sanzo, Anna Aventín, Anna Puiggros, Rosa Collado, Cecilia Heras, Carolina Muñoz, Julio Delgado, Margarita Ortega, María-Teresa González, Isabel Marugán, Ignacio de la Fuente, Isabel Recio, Francesc Bosch, Blanca Espinet, Marcos González, Jesús-María Hernández-Rivas, José-Ángel Hernández
The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy-four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39-58) vs 30 months (CI95%, 22-38) (P = 0...
June 2016: Hematological Oncology
https://www.readbyqxmd.com/read/25680074/acute-myeloid-leukemia-with-inv-3-q21q26-2-or-t-3-3-q21-q26-2-clinical-and-biological-features-and-comparison-with-other-acute-myeloid-leukemias-with-cytogenetic-aberrations-involving-long-arm-of-chromosome-3
#7
Jose Maria Raya, Taida Martín-Santos, Elisa Luño, Carmen Sanzo, Maria Luz Perez-Sirvent, Esperanza Such, José Tomás Navarro, Fuensanta Millá, Esther Alonso, Alicia Domingo, María Rozman, Marina Díaz-Beva, Ana Batlle, Sonia González-de-Villambrosia, Esperanza Tuset, Teresa Vallespí, Margarita Ortega, Alfredo Bermejo, Marisa Martín-Ramos, Valeria Peri, Francesc Solé, Lourdes Florensa
Objectives To compare, from a biological and clinical perspective, a significant group of patients with AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) with another group of AML carrying different abnormalities of 3q at q21 or q26, the latter named as the AML abn(3q) group. Methods We developed a national survey with the participation of 13 Spanish hospitals, and retrospectively reviewed (from 1990 to 2010) these subtypes of AML. Fifty-five patients were collected: 35 with AML inv(3)/t(3;3) and 20 with AML abn(3q)...
February 13, 2015: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/25015251/-incidence-of-haematological-neoplasms-in-castilla-y-le%C3%A3-n-spain
#8
José Antonio Rodríguez-García, Lourdes Vázquez, Fernando Ramos, Beatriz Cuevas, Alejandro Martín, Alicia Smucler, Dulce Nombre Guerola, Alberto Cantalapiedra, José María Alonso, Silvia Fernández, Eva Díez, María Jesús Rodríguez, María José Calmuntia, Carlos Aguilar, Magdalena Sierra, José Antonio Gracia, María José Cebeira, Rosa Cantalejo
BACKGROUND AND OBJECTIVE: We aimed to assess the incidence of haematological neoplasms (HNs) in Castilla y León (2,5 million inhabitants) and its distribution by age, gender and histological type. PATIENTS AND METHOD: The epidemiological profile based on the described variables of the 10,943 HNs diagnosed during a 10-years period was analyzed, compared with other studies. RESULTS: The overall age-adjusted incidence was 29.4 cases/10(5) inhabitants-year, with some geographical differences...
June 8, 2015: Medicina Clínica
https://www.readbyqxmd.com/read/24915757/interstitial-13q14-deletions-detected-in-the-karyotype-and-translocations-with-concomitant-deletion-at-13q14-in-chronic-lymphocytic-leukemia-different-genetic-mechanisms-but-equivalent-poorer-clinical-outcome
#9
MULTICENTER STUDY
Anna Puiggros, Marta Venturas, Marta Salido, Gonzalo Blanco, Concepción Fernandez-Rodriguez, Rosa Collado, Alberto Valiente, Neus Ruiz-Xivillé, Ana Carrió, Francisco José Ortuño, Elisa Luño, María José Calasanz, María Teresa Ardanaz, María Ángeles Piñán, Elisabet Talavera, María Teresa González, Margarita Ortega, Isabel Marugán, Ana Ferrer, Eva Gimeno, Beatriz Bellosillo, Julio Delgado, José Ángel Hernández, Jesús María Hernández-Rivas, Blanca Espinet
Deletion of 13q14 as the sole abnormality is a good prognostic marker in chronic lymphocytic leukemia (CLL). Nonetheless, the prognostic value of reciprocal 13q14 translocations [t(13q)] with related 13q losses has not been fully elucidated. We described clinical and biological characteristics of 25 CLL patients with t(13q), and compared with 62 patients carrying interstitial del(13q) by conventional G-banding cytogenetics (CGC) [i-del(13q)] and 295 patients with del(13q) only detected by fluorescence in situ hybridization (FISH) [F-del(13q)]...
September 2014: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/24824767/multilineage-dysplasia-is-associated-with-a-poorer-prognosis-in-patients-with-de-novo-acute-myeloid-leukemia-with-intermediate-risk-cytogenetics-and-wild-type-npm1
#10
COMPARATIVE STUDY
María Rozman, José-Tomás Navarro, Leonor Arenillas, Anna Aventín, Teresa Giménez, Esther Alonso, Granada Perea, Mireia Camós, Mayda Navarrete, Esperanza Tuset, Lourdes Florensa, Fuensanta Millá, Josep Nomdedéu, Esmeralda de la Banda, Marina Díaz-Beyá, Marta Pratcorona, Ana Garrido, Blanca Navarro, Salut Brunet, Jorge Sierra, Jordi Esteve
Acute myeloid leukemia (AML) with myelodysplasia-related changes is characterized by the presence of multilineage dysplasia (MLD), frequently related to high-risk cytogenetics and poor outcome. However, the presence of MLD does not modify the favorable prognostic impact of NPM1 mutation. The prognosis of patients with AML presenting marked dysplasia lacking high-risk cytogenetics and NPM1 mutation is uncertain. We evaluated the prognostic impact of MLD in 177 patients with intermediate-risk cytogenetics AML (IR-AML) and wild-type NPM1...
October 2014: Annals of Hematology
https://www.readbyqxmd.com/read/24500546/-institutional-renovation-and-scientific-modernization-the-creation-of-the-instituto-de-investigaciones-hematol%C3%A3-gicas-during-the-mid-1950s
#11
José Buschini
Using documentary sources, this work analyzes the creation and initial functioning of the Instituto de Investigaciones Hematológicas (Institute of Hematological Research) of the National Academy of Medicine (Buenos Aires, Argentina) in the context of the scientific modernization initiated within the country during the mid-1950s. Particular attention is paid to the generation of material bases and institutional and cultural mechanisms for the development of scientific research and of clinical practices guided by procedures and techniques rooted in the basic sciences...
December 2013: Salud Colectiva
https://www.readbyqxmd.com/read/24144641/smoldering-multiple-myeloma-requiring-treatment-time-for-a-new-definition
#12
REVIEW
Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, S Vincent Rajkumar, Robert A Kyle, Rafael Fonseca, Prashant Kapoor, P Leif Bergsagel, Arleigh McCurdy, Morie A Gertz, Martha Q Lacy, John A Lust, Stephen J Russell, Steven R Zeldenrust, Craig Reeder, Vivek Roy, Francis Buadi, David Dingli, Suzanne R Hayman, Nelson Leung, Yi Lin, Joseph Mikhael, Shaji K Kumar
Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myeloma-related events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone...
December 19, 2013: Blood
https://www.readbyqxmd.com/read/23869550/biallelic-losses-of-13q-do-not-confer-a-poorer-outcome-in-chronic-lymphocytic-leukaemia-analysis-of-627-patients-with-isolated-13q-deletion
#13
Anna Puiggros, Julio Delgado, Ana Rodriguez-Vicente, Rosa Collado, Anna Aventín, Elisa Luño, Javier Grau, José Ángel Hernandez, Isabel Marugán, Maite Ardanaz, Teresa González, Alberto Valiente, Mar Osma, Maria José Calasanz, Carmen Sanzo, Ana Carrió, Margarita Ortega, Rodrigo Santacruz, Pau Abrisqueta, Eugènia Abella, Francesc Bosch, Félix Carbonell, Francesc Solé, Jesús Maria Hernández, Blanca Espinet
Losses in 13q as a sole abnormality confer a good prognosis in chronic lymphocytic leukaemia (CLL). Nevertheless, its heterogeneity has been demonstrated and the clinical significance of biallelic 13q deletions remains controversial. We compared the clinico-biological characteristics of a series of 627 patients harbouring isolated 13q deletions by fluorescence in situ hybridization (FISH), either monoallelic (13q × 1), biallelic (13q × 2), or the coexistence of both clones (13qM). The most frequent 13q deletion was 13q × 1 (82·1%), while 13q × 2 and 13qM represented 8·6% and 9·3% of patients respectively...
October 2013: British Journal of Haematology
https://www.readbyqxmd.com/read/22712840/prognostic-role-of-gender-in-diffuse-large-b-cell-lymphoma-treated-with-rituximab-containing-regimens-a-fondazione-italiana-linfomi-grupo-de-estudos-em-mol%C3%A3-stias-onco-hematol%C3%A3-gicas-retrospective-study
#14
Angelo M Carella, Carmino A de Souza, Stefano Luminari, Luigi Marcheselli, Annalisa Chiappella, Alice di Rocco, Marina Cesaretti, Andrea Rossi, Luigi Rigacci, Gianluca Gaidano, Francesco Merli, Michele Spina, Caterina Stelitano, Stefan Hohaus, Anna Barbui, Benedetta Puccini, Eliana C Miranda, Annalisa Guida, Massimo Federico
Male gender was recently reported as an adverse prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). We conducted a retrospective study of adult patients with DLBCL initially treated with rituximab containing regimens between 2001 and 2007. Patients were identified from the clinical archives of 43 Italian and Brazilian institutions. The principal endpoint was overall survival (OS). One thousand seven hundred and ninety-three patients were fully eligible for the study...
January 2013: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/22224845/chronic-lymphocytic-leukaemia-with-17p-deletion-a-retrospective-analysis-of-prognostic-factors-and-therapy-results
#15
MULTICENTER STUDY
Julio Delgado, Blanca Espinet, Ana C Oliveira, Pau Abrisqueta, Javier de la Serna, Rosa Collado, Javier Loscertales, Montserrat Lopez, Jose A Hernandez-Rivas, Christelle Ferra, Angel Ramirez, Josep M Roncero, Cristina Lopez, Anna Aventin, Anna Puiggros, Eugenia Abella, Felix Carbonell, Dolors Costa, Anna Carrio, Marcos Gonzalez
Patients with chronic lymphocytic leukaemia (CLL) whose tumour cells harbour a 17p deletion (17p-) are universally considered to have a poor prognosis. The deletion can be detected at diagnosis or during the evolution of the disease, particularly in patients who have received chemotherapy. We sought to evaluate the natural history of patients with 17p- CLL, identify predictive factors within this prognostic subgroup, and evaluate the results of different therapeutic approaches. Data from 294 patients with 17p- CLL followed up at 20 different institutions was retrospectively collected and analysed...
April 2012: British Journal of Haematology
https://www.readbyqxmd.com/read/20625122/therapy-related-myeloid-neoplasms-in-patients-with-acute-promyelocytic-leukemia-treated-with-all-trans-retinoic-acid-and-anthracycline-based-chemotherapy
#16
Pau Montesinos, José D González, José González, Chelo Rayón, Elena de Lisa, Maria L Amigo, Gert J Ossenkoppele, María J Peñarrubia, Manuel Pérez-Encinas, Juan Bergua, Guillermo Debén, María J Sayas, Javier de la Serna, Josep M Ribera, Javier Bueno, Gustavo Milone, Concha Rivas, Salut Brunet, Bob Löwenberg, Miguel Sanz
PURPOSE: We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). PATIENTS AND METHODS: From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy...
August 20, 2010: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/20591449/-from-conventional-cytogenetics-to-microarrays-fifty-years-of-philadelphia-chromosome
#17
REVIEW
Jesús M Hernández, Isabel Granada, Francesc Solé et al.
In 1960 Ph-chromosome was found associated with the presence of chronic myelogenous leukemia. In these 50 years an increasing number of cytogenetic abnormalities have been found associated with hematological malignancies. The presence of these abnormalities is not only important for the diagnosis of the patient, but it also contributes to the prognosis of patients with leukemia or lymphoma. For this reason the WHO classification of hematological disease has included these studies for the correct characterization of leukemias and lymphomas...
July 23, 2011: Medicina Clínica
https://www.readbyqxmd.com/read/20447898/-aids-related-lymphomas-histopathological-subtypes-and-association-with-epstein-barr-virus-and-human-herpes-virus-type-8
#18
Marcelo Corti, Marcela de Dios Soler, Patricia Bare, María F Villafañe, Miguel De Tezanos Pinto, Raúl Perez Bianco, Marina Narbaitz
Non-Hodgkin lymphomas (NHL) of the B-cell type are the second most common neoplasm among patients with human immunodeficiency virus (HIV) infection and AIDS. Here, we evaluated 48 cases of AIDS-related lymphomas (ARL) diagnosed at the Histopathological Division of the Instituto de Investigaciones Hematológicas of the National Academy of Medicine. Five were females and 43 were males with a median of age of 37 years at the time of the diagnosis. Micrometer sections were prepared and stained with hematoxilin-eosin; immunohistochemical examination for the presence of Epstein-Barr virus (EBV) was carried out in 48/48 cases...
2010: Medicina
https://www.readbyqxmd.com/read/18820995/refractory-anemia-with-ringed-sideroblasts-associated-with-thrombocytosis-comparative-analysis-of-marked-with-non-marked-thrombocytosis-and-relationship-with-jak2-v617f-mutational-status
#19
MULTICENTER STUDY
J M Raya, L Arenillas, A Domingo, B Bellosillo, G Gutiérrez, E Luño, M A Piñán, M Barbón, M L Pérez-Sirvent, M J Muruzábal, L Yánez, L García, A Lemes, J T Navarro, A Elosegi, M A Cortés, A Villegas, M A Durán, M Ardanaz, L Florensa et al.
The World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues (2001) defined a provisional entity named refractory anemia with ringed sideroblasts associated to marked thrombocytosis (RARS-MT). Diagnosis of RARS-MT requires more than 15% of ringed sideroblasts in bone marrow aspirate and the existence of a thrombocytosis in blood, with a platelet count above 600 x 10(9)/L. Nevertheless, controversy exists regarding this platelet count "cut-off" value and, when RARS-MT was defined, the JAK2 mutation and its importance in the study of myeloproliferative disorders was unknown...
November 2008: International Journal of Hematology
https://www.readbyqxmd.com/read/16154839/identification-of-novel-cytogenetic-markers-with-prognostic-significance-in-a-series-of-968-patients-with-primary-myelodysplastic-syndromes
#20
COMPARATIVE STUDY
Francesc Solé, Elisa Luño, Carmen Sanzo, Blanca Espinet, Guillermo F Sanz, José Cervera, María José Calasanz, Juan Cruz Cigudosa, Fuensanta Millà, Josep Maria Ribera, Encarna Bureo, Maria Luisa Marquez, Eva Arranz, Lourdes Florensa
BACKGROUND AND OBJECTIVES: The main prognostic factors in myelodysplastic syndromes (MDS) are chromosomal abnormalities, the proportion of blasts in bone marrow and number and degree of cytopenias. A consensus-defined International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in MDS has been developed, but its prognostic value in a large and independent series remains unproven. Furthermore, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities of uncertain prognostic significance at present...
September 2005: Haematologica
keyword
keyword
73177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"